– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy –…
Encouraging overall response rate of 46% and disease control rate of 98% with a median duration of response of 11.2…
Buyer Registration Link HONG KONG SAR - Media OutReach - 22 October 2023 - Organised by the Hong Kong Trade…
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab showed a confirmed objective response rate of 79% Two ongoing phase 3…
XIAMEN, China--(BUSINESS WIRE)--On October 20th, the 24th Conference on The Electric Power Supply Industry kicked off in Xiamen, attended by…
GURUGRAM, India & NEW YORK--(BUSINESS WIRE)--$MMYT #Fiscal2024--MakeMyTrip Limited (Nasdaq: MMYT) plans to report its fiscal 2024 second quarter financial and…
Foundation Medicine will transfer FoundationOne®Liquid CDx technology to Sequanta in November 2023 and FoundationOne®CDx technology in March 2024 The partnership…
BEIJING, CHINA - Media OutReach - 21 October 2023 - On the evening of October 9th at 8:00 pm, the…
Event spotlights next-generation memory solutions for applications such as cloud, edge devices and automotive vehicles New technologies and products include…
DUBLIN--(BUSINESS WIRE)--The digital lending scene is undergoing a seismic shift, as highlighted by a recent news article on American Banker…